Overcoming the suppressive activity of myeloid-derived suppressor cells may improve the efficacy of immune checkpoint inhibitors in treating melanoma.
CU Anschutz
Anschutz Cancer Pavilion
1665 North Aurora Court
2004
Aurora, CO 80045
Late-Stage Melanoma: Experimental Drug Combo Puts 50% of Patients into Remission
minute read
by Medical News Today | January 3, 2023
